Aspire Biopharma Holdings, Inc. 10-Q filing
Filed 2026-05-15 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001493152-26-023802
- Form type
- 10-Q
- CIK
- 0001847345
- Primary document
- https://www.sec.gov/Archives/edgar/data/1847345/000149315226023802/form10-q.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Aspire Biopharma Holdings, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $28,353 | - | - |
| Cost Of Revenue | $22,603 | - | - |
| Gross Profit | $5,750 | - | - |
| Operating Income | $-1.6M | - | - |
| Net Income | $-3.2M | - | - |
| Eps Basic | -20.57 | - | - |
| Eps Diluted | -20.57 | - | - |
| Cash And Equivalents | $5.9M | - | - |
| Total Assets | $7.1M | - | - |
| Total Liabilities | $3.2M | - | - |
| Shareholders Equity | $3.9M | - | - |
| Operating Cash Flow | $-3.0M | - | - |